Gaxos.ai Q3: Revenue $2.81M, Loss Narrows to $0.08/Share, Cash Pile $13.3M
GXAI sits 24% above its 52-week low of $0.342 on elevated volume (20× avg).
Summary
Gaxos.ai's Q3 2026 10-Q shows revenue of $2.81 million and a narrowed net loss of $977,004 ($0.08 per share), backed by $12.7 million of working capital — but shares outstanding nearly doubled to 13.75 million on ATM sales and warrant exercises.
Key Events · Earnings and Guidance · GXAI
-
Q3 Revenue $2.81M, Loss Narrows
Revenue of $2,814,527 versus $498,271 a year earlier; net loss fell to $977,004 from $1,140,873 and net loss per share improved to $0.08 from $0.14.
-
Nine-Month Operating Loss Widens
Operating loss for the nine months grew to $5,526,299 from $3,689,144 as advertising and marketing rose to $8,523,776 from $1,552,215.
-
Balance Sheet: $12.7M Working Capital
Cash of $1,895,334 plus short-term investments of $11,402,526 produced working capital of $12,693,960; management says this funds operations for the next twelve months against $4,538,025 of nine-month operating cash burn.
-
Share Count Nearly Doubles
Shares outstanding rose to 13,752,288 from 7,123,453 at December 31, 2025, including 3,621,181 ATM shares and 3,007,654 shares issued on the August warrant exercise; 7,667,296 warrants remain outstanding at a $2.58 weighted average exercise price.
Analysis · GXAI · Technology
Revenue is real and growing fast, but the business mix has shifted: $1.96 million of the $2.81 million quarter came from RNK Health administrative services, with $855,907 from AI app subscriptions. The quarter's loss narrowed to $977,004 from $1,140,873, yet the nine-month operating loss widened to $5,526,299 from $3,689,144 because advertising and marketing ran at $8,523,776 versus $1,552,215 a year ago — the company is buying growth. Funding is not the near-term issue: $1,895,334 of cash plus $11,402,526 of short-term investments gives $12,693,960 of working capital, and management says that covers the next twelve months. The cost is dilution. Shares outstanding went from 7,123,453 at December 31, 2025 to 13,752,288, driven by 3,621,181 ATM shares and 3,007,654 shares from the August warrant inducement, and 7,667,296 warrants remain outstanding at a $2.58 weighted average strike — far above today's price, so they are unlikely to be exercised soon. Against a Nasdaq minimum-bid deficiency notice received October 1, 2026, the equity story now rests on whether subscription and health-services revenue can scale before the marketing spend has to be pulled back.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GXAI was trading at $0.42 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.34 to $2.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.